Streamlining Palliative & Hospice Biologics Prior Auth
Klivira optimizes the complex process of palliative & hospice biologics prior auth, ensuring patients receive timely access to critical therapies while reducing administrative overhead.
For revenue cycle directors and prior authorization coordinators in palliative care and hospice settings, managing prior authorizations for high-cost biologics presents unique challenges. The focus on quality of life and symptom management necessitates efficient approval workflows for specialty medications, including TNF inhibitors, IL-17/23 inhibitors, and JAK inhibitors, which are often crucial for managing complex symptoms. Klivira addresses these complexities by automating key steps in the prior authorization process.
The Nuances of Biologics PA in Palliative & Hospice Care
Palliative and hospice care prioritize patient comfort and dignity, making timely access to effective therapies paramount. While high-volume prior authorization categories often include hospice levels of care, palliative medications, and DME, biologics represent a distinct challenge due to their cost, specific clinical criteria, and the need for ongoing re-authorization. Ensuring rapid approval for these agents, which may manage severe pain, inflammatory conditions, or other debilitating symptoms, directly impacts patient quality of life.
Automating Biologics Prior Authorization Workflows
Klivira's platform automates critical steps in the biologics prior authorization workflow, adapting to the unique clinical context of palliative and hospice care. This includes intelligent classification of indications, automated checks against step therapy requirements, and routing based on biosimilar substitution policies. By integrating directly with EMRs, Klivira gathers necessary clinical documentation efficiently, reducing manual effort and potential delays.
Key Automation Capabilities for Palliative & Hospice Biologics PA
- Indication-aware routing: Classifies specialty and disease state from EMR diagnoses, ensuring PA requests align with palliative goals.
- Step therapy validation: Automatically pulls prior-line therapy history to satisfy payer requirements, even for symptom-focused treatments.
- Biosimilar substitution logic: Applies per-payer mandates for biosimilar trials, streamlining compliance.
- Screening documentation: Extracts relevant screening results (e.g., TB, hepatitis) from FHIR data for submission.
- Periodic re-authorization management: Manages 6 or 12-month re-authorization cycles, adapting to evolving patient care plans.
- Benefit routing: Distinguishes medical vs. pharmacy benefit for agents with varying administration modes.
EMR and Payer Integration for Seamless Workflows
Klivira integrates with leading EMRs via SMART on FHIR, extracting essential clinical data such as medication orders, diagnosis codes, and progress notes relevant to palliative care. This data fuels automated prior authorization submissions through X12 278 transactions and direct connections to payer portals, minimizing manual data entry and ensuring data accuracy. The system is designed to handle the diverse documentation conventions found across specialties, including those common in end-of-life care.
Addressing High-Cost Specialty Drug Challenges
Biologics, including TNF inhibitors, IL-17/23 inhibitors, IL-6 inhibitors, and JAK inhibitors, represent a significant portion of high-cost specialty drug prior authorizations. The CAQH Index consistently highlights the administrative burden of specialty pharmacy PA. Klivira's solution is engineered to mitigate this burden by automating the complex criteria associated with these drug classes, from indication-specific requirements to screening protocols and re-authorization triggers, even within the sensitive context of palliative and hospice care.
Frequently asked questions
How does Klivira handle the evolving goals of care in palliative settings for biologics PA?
Klivira's system is designed to integrate with EMR data, reflecting current diagnoses and treatment plans. While the system automates the documentation and submission process, the clinical team's justification, which outlines how the biologic supports the patient's palliative goals (e.g., symptom management, quality of life), remains central. Periodic re-authorizations are managed to align with these evolving care plans.
Can Klivira differentiate between palliative use and curative use for the same biologic?
Klivira's indication classification capability identifies the specialty and disease state from EMR diagnoses. While the system doesn't make clinical judgments, it processes the PA request based on the documented indication and justification provided by the care team, which would reflect whether the use is palliative or curative. This ensures the correct payer criteria are applied.
What types of documentation does Klivira pull from the EMR for biologics in hospice care?
Klivira leverages SMART on FHIR integration to extract critical data points from the EMR. This includes diagnosis codes (ICD-10), medication orders, lab results (e.g., for TB or hepatitis screenings), and relevant progress notes that describe symptom burden, prior therapies, and the clinical rationale for the biologic within the hospice care plan.
Does Klivira support biosimilar substitution policies for biologics used in palliative care?
Yes, Klivira's workflow incorporates biosimilar substitution routing. The system applies per-payer biosimilar mandates, identifying when a biosimilar must be tried first according to the payer's policy. This ensures compliance with payer requirements while facilitating access to appropriate, cost-effective therapies.
How does Klivira handle re-authorization for biologics in palliative/hospice settings?
Klivira automates the management of periodic re-authorization cycles, typically 6 or 12 months, as specified by payers for chronic treatments. For palliative and hospice care, the system prompts for necessary updated clinical documentation regarding continued disease activity or response, allowing the care team to provide current justification aligned with the patient's evolving condition and goals of care.
Related coverage
Other palliative-hospice prior auth workflows
Ready to automate this workflow for this specialty?
See how Klivira automates prior authorizations for your team.
Request a demo